CN115951055A - 一种癌症相关蛋白及其抗体和应用 - Google Patents
一种癌症相关蛋白及其抗体和应用 Download PDFInfo
- Publication number
- CN115951055A CN115951055A CN202211594607.8A CN202211594607A CN115951055A CN 115951055 A CN115951055 A CN 115951055A CN 202211594607 A CN202211594607 A CN 202211594607A CN 115951055 A CN115951055 A CN 115951055A
- Authority
- CN
- China
- Prior art keywords
- protein
- monoclonal antibody
- kit
- hcrp1
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 25
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 24
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 7
- 201000011510 cancer Diseases 0.000 title claims abstract description 7
- 238000001514 detection method Methods 0.000 claims abstract description 31
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 16
- 101000641296 Homo sapiens Vacuolar protein sorting-associated protein 37A Proteins 0.000 claims abstract 7
- 102100034324 Vacuolar protein sorting-associated protein 37A Human genes 0.000 claims abstract 7
- 239000000243 solution Substances 0.000 claims description 23
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 claims description 13
- 238000005406 washing Methods 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 12
- 238000010790 dilution Methods 0.000 claims description 11
- 239000012895 dilution Substances 0.000 claims description 11
- 239000006180 TBST buffer Substances 0.000 claims description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 5
- 238000002331 protein detection Methods 0.000 claims description 3
- 239000011859 microparticle Substances 0.000 claims 2
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 101001057137 Homo sapiens Melanoma-associated antigen E1 Proteins 0.000 description 30
- 102100027260 Melanoma-associated antigen E1 Human genes 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 13
- 210000004408 hybridoma Anatomy 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 206010003445 Ascites Diseases 0.000 description 7
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 description 5
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 238000007865 diluting Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 201000000050 myeloid neoplasm Diseases 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 4
- 230000007910 cell fusion Effects 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 239000006249 magnetic particle Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000011725 BALB/c mouse Methods 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 229960002446 octanoic acid Drugs 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000007864 suspending Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- LHGMHYDJNXEEFG-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]iminocyclohexa-2,5-dien-1-one Chemical compound C1=CC(N(C)C)=CC=C1N=C1C=CC(=O)C=C1 LHGMHYDJNXEEFG-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- MUUGCDGGIVCSDT-UHFFFAOYSA-N [NH4+].[NH4+].[O-]S([O-])(=O)=O.CCCCCCCC(O)=O Chemical compound [NH4+].[NH4+].[O-]S([O-])(=O)=O.CCCCCCCC(O)=O MUUGCDGGIVCSDT-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- -1 acridine ester Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000000504 luminescence detection Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000013094 purity test Methods 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211594607.8A CN115951055A (zh) | 2022-12-13 | 2022-12-13 | 一种癌症相关蛋白及其抗体和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211594607.8A CN115951055A (zh) | 2022-12-13 | 2022-12-13 | 一种癌症相关蛋白及其抗体和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115951055A true CN115951055A (zh) | 2023-04-11 |
Family
ID=87288701
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211594607.8A Pending CN115951055A (zh) | 2022-12-13 | 2022-12-13 | 一种癌症相关蛋白及其抗体和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115951055A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116482369A (zh) * | 2023-06-13 | 2023-07-25 | 天津市协和医药科技集团有限公司 | 一种癌胚抗原检测试剂盒 |
CN117820489A (zh) * | 2024-01-15 | 2024-04-05 | 广州杰博生物科技有限公司 | 一种抗体融合蛋白及其制备方法与应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105308070A (zh) * | 2013-06-14 | 2016-02-03 | 拜耳制药股份公司 | 抗tweakr抗体及其用途 |
CN106029875A (zh) * | 2014-02-14 | 2016-10-12 | 塞勒克提斯公司 | 为了靶向存在于免疫细胞和病理细胞两者上的抗原而工程化的免疫治疗细胞 |
CN106977609A (zh) * | 2017-04-19 | 2017-07-25 | 刘崇东 | 一种融合蛋白、制备方法及其应用 |
CN110225928A (zh) * | 2017-01-24 | 2019-09-10 | 三生国健药业(上海)股份有限公司 | 抗pd-1单克隆抗体及其制备方法和应用 |
CN113286811A (zh) * | 2018-07-30 | 2021-08-20 | 南加利福尼亚大学 | 改善过继性细胞疗法的效力和安全性 |
CN113583134A (zh) * | 2020-04-30 | 2021-11-02 | 天辰生物医药(苏州)有限公司 | 分离的抗原结合蛋白及其用途 |
-
2022
- 2022-12-13 CN CN202211594607.8A patent/CN115951055A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105308070A (zh) * | 2013-06-14 | 2016-02-03 | 拜耳制药股份公司 | 抗tweakr抗体及其用途 |
CN106029875A (zh) * | 2014-02-14 | 2016-10-12 | 塞勒克提斯公司 | 为了靶向存在于免疫细胞和病理细胞两者上的抗原而工程化的免疫治疗细胞 |
CN110225928A (zh) * | 2017-01-24 | 2019-09-10 | 三生国健药业(上海)股份有限公司 | 抗pd-1单克隆抗体及其制备方法和应用 |
CN106977609A (zh) * | 2017-04-19 | 2017-07-25 | 刘崇东 | 一种融合蛋白、制备方法及其应用 |
CN113286811A (zh) * | 2018-07-30 | 2021-08-20 | 南加利福尼亚大学 | 改善过继性细胞疗法的效力和安全性 |
CN113583134A (zh) * | 2020-04-30 | 2021-11-02 | 天辰生物医药(苏州)有限公司 | 分离的抗原结合蛋白及其用途 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116482369A (zh) * | 2023-06-13 | 2023-07-25 | 天津市协和医药科技集团有限公司 | 一种癌胚抗原检测试剂盒 |
CN116482369B (zh) * | 2023-06-13 | 2023-08-25 | 天津市协和医药科技集团有限公司 | 一种癌胚抗原检测试剂盒 |
CN117820489A (zh) * | 2024-01-15 | 2024-04-05 | 广州杰博生物科技有限公司 | 一种抗体融合蛋白及其制备方法与应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN115951055A (zh) | 一种癌症相关蛋白及其抗体和应用 | |
CN111303254A (zh) | 新型冠状病毒(SARS-CoV-2)抗原检测试剂盒 | |
CN107022029B (zh) | 高特异高灵敏检测甲胎蛋白的单克隆抗体及试剂盒和应用 | |
CN107022030B (zh) | 检测甲胎蛋白的单克隆抗体及试剂盒和应用 | |
CN111273042A (zh) | 抗缪勒氏管激素检测试剂盒 | |
CN113138276B (zh) | 用于检测HBcAg的方法及抗体 | |
WO2022099465A1 (zh) | 杂交瘤细胞株9c1、plgf-1单克隆抗体及其制备方法和应用 | |
CN111217907B (zh) | 抗amh单克隆抗体及其应用 | |
CN113717283B (zh) | 一种抗乙型肝炎病毒e抗原的单克隆抗体及其应用 | |
CN109082413B (zh) | 抗人IgG单克隆抗体、其杂交瘤细胞株及应用 | |
CN109112113B (zh) | 抗人IgG的单克隆抗体、杂交瘤细胞株、试剂盒及其应用 | |
CN109112114B (zh) | 抗人IgG单克隆抗体、其杂交瘤细胞株及应用 | |
CN110540969B (zh) | 人肺炎支原体表面蛋白单克隆抗体及抗原捕获elisa试剂盒 | |
CN110895279A (zh) | 一种检测人附睾分泌蛋白4的化学发光试剂盒 | |
WO2018036435A1 (zh) | 杂交瘤细胞株scca1及其分泌的单克隆抗体和应用 | |
CN109280644B (zh) | 抗人IgG单克隆抗体、其杂交瘤细胞株及应用 | |
CN116925218A (zh) | 小热休克蛋白hspb1的抗体、抗体组合物、杂交瘤细胞株及其应用 | |
CN108588030B (zh) | 抗人IgM单克隆抗体、其杂交瘤细胞株及应用 | |
CN110531077B (zh) | 间皮素免疫组化检测试剂盒 | |
WO2020099828A1 (en) | Monoclonal antibodies against ambra-1 | |
CN113603770B (zh) | 一种新冠病毒核蛋白抗体和应用 | |
CN113929776B (zh) | 抗真菌(1,3)-β-D葡聚糖单克隆抗体、其编码基因及其表达和应用 | |
CN109266620B (zh) | 抗人IgG单克隆抗体、其杂交瘤细胞株及应用 | |
CN113150157A (zh) | 一种用于检测血清中vegf含量的抗体对及其用途 | |
CN113754761A (zh) | 一种新冠病毒检测用单抗 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240103 Address after: 150077 Unit 3, Building 7, Evergrande International Center, Qunli Avenue, Daoli District, Harbin City, Heilongjiang Province Applicant after: Heilongjiang Lianpeng Biotechnology Co.,Ltd. Address before: No. 12, Sanlian Road, Huangcun, Tianhe District, Guangzhou City, Guangdong Province, 510660 Applicant before: Guangzhou Shuntai Biomedical Technology Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240418 Address after: Building 1, No. 2 Helong 1st Road, Baiyun District, Guangzhou City, Guangdong Province, 510470 Applicant after: Guangdong Zhuofeng Biotechnology Co.,Ltd. Country or region after: China Address before: 150077 Unit 3, Building 7, Evergrande International Center, Qunli Avenue, Daoli District, Harbin City, Heilongjiang Province Applicant before: Heilongjiang Lianpeng Biotechnology Co.,Ltd. Country or region before: China |